Monitoring hepatitis B reactivation in immunosuppressed patients
Part of Infections clinical trials.
This study tracks patients who carry hepatitis B antibodies and are about to start immunosuppressive therapy (medications that weaken the immune system). Researchers want to understand when and how hepatitis B can reactivate in these patients and how to prevent it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have hepatitis B antibodies in your blood (Anti-HBc IgG positive)
- Be eligible to start immunosuppressive therapy (medications that lower immune function)
- Be able to attend follow-up visits regularly
- Not have already decided to withdraw from the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking the antiviral medicine entecavir before and after a stem cell transplant can prevent hepatitis B from “waking up” again. It may help protect your liver during a high-risk treatment period.
This trial tests an immunomodulatory therapy for people with chronic hepatitis B who have already cleared the surface antigen (HBsAg) with a specific treatment. It aims to understand why some people achieve a cure and how to improve outcomes.
This study looks at people who had hepatitis B in the past (but are not currently infected) and are getting a stem cell transplant. The goal is to see if a simple model can predict whether the hepatitis B virus might come back, so doctors can monitor and treat it early.
This trial is for people with chronic hepatitis B who have already cleared the virus with interferon treatment. It tests ongoing strategies to help maintain their health and prevent the virus from coming back.
This early-phase study tests whether a hepatitis B vaccine (with an added ingredient to boost the immune response) can safely help people with long-term hepatitis B who are already on antiviral therapy. It is mainly looking at safety and how the immune system responds.
This study looks at how the immune system changes over time in people with chronic hepatitis B. It will help doctors better understand the stages of the disease to guide treatment decisions.
Hear when a new HBV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.